# Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

> **NCT06660524** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 196 (estimated)

## Conditions studied

- Degenerative Heart Valve Disease
- Heart Valve Calcification
- Chronic Kidney Disease(CKD)
- Calcium-Phosphorus Metabolism Disorders

## Interventions

- **DRUG:** Sevelamer
- **DRUG:** Calcium carbonate

## Key facts

- **NCT ID:** NCT06660524
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660524, "Calcium-Phosphorus Regulation Therapy on Heart Valve Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06660524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*